Adriamycin

Doxorubicin (Adriamycin) is a fluorescent anthracycline antitumor antibiotic that inhibits Topoisomerase I/II, induces apoptosis and autophagy, downregulates the AMPK signaling pathway, and is commonly used in cancer chemotherapy as well as in models of nephritis and heart failure.

Doxorubicin hydrochloride is an anthracycline antibiotic with cytotoxic and antitumor activity. It is an effective inhibitor of human DNA topoisomerase I and II, with IC50 values of 0.8 μM and 2.67 μM, respectively. In addition to inhibiting DNA topoisomerases, it can reduce the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase. Doxorubicin hydrochloride also induces apoptosis and autophagy. In animal studies, it is commonly used to induce models of acute renal failure, chronic kidney injury, and heart failure.

Adriamycin Aglycone, also known as Doxorubicinone, is an oncolytic agent. It is a metabolite of Doxorubicin which binds to the DNA minor-groove.

7-Deoxyadriamycinol aglycone is an adriamycin metabolite.

N-Trifluoroacetyladriamycin is a metabolite of Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar). Valrubicin is a chemotherapy drug utilized to treat bladder cancer. Valrubicin is the anthracycline doxorubicin analog and is administ

Doxorubicinol is the major circulating metabolite of doxorubicin with antineoplastic acitivity.

Doxorubicinol hydrochloride, also known as 13-Dihydroadriamycin hydrochloride, is a secondary alcohol metabolite derived from Doxorubicin.

Esorubicin is a synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Epirubicin (4'-Epidoxorubicin) is an anthracycline antibiotic that acts as a Topoisomerase II inhibitor. It exerts its antitumor effects by intercalating into DNA base pairs, inhibiting DNA replication and transcription, and inducing DNA strand breaks/apoptosis. Epirubicin is widely used in the treatment of breast, gastric, lung, and ovarian cancers.

Monoxerutin (MonoHER) is a vasodilator with antioxidant activity that prevents adriamycin-induced cardiotoxicity in mice and is used in the study of acute respiratory syndrome.

Epirubicin hydrochloride (Pharmorubicin) is an adriamycin derivative, a topoisomerase (Topo) inhibitor, and a Forkhead box protein p3 (Foxp3) inhibitor. Epirubicin hydrochloride has antitumor activity.

Feudomycin A (13-Deoxydaunorubicin), an anthracycline antibiotic produced by Streptomyces mutans, can be converted to adriamycin with potential antitumor activity by specific microorganisms.

MC3343, a DNMT inhibitor with IC50 values of 5.7 μM for DNMT1 and 1.7 μM for DNMT3a, affects tumor proliferation by blocking osteosarcoma cells in the G1 or G2/M phase and induces osteogenic differentiation by specifically re-expressing genes that regulate this physiological process, and is able to show synergistic effects in combination with adriamycin and cisplatin (CDDP).

YM-53601 is a potent squalene synthase (SQS) inhibitor that inhibits adipogenic biosynthesis and lipid secretion in rodents.YM-53601 is a cholesterol-lowering agent that inhibits farnesyl diphosphate farnesyltransferase 1 (FDFT1).YM-53601 exhibits potential antiviral activity and enhances adriamycin-mediated HCC arrest and cell death in vivo. MJN228 is a lipid-based enzyme.

A 30312 is a fused indole, which overcomes multidrug resistance in P388/Adr cells in vitro. It potentiates the cytotoxicity of the antitumor drugs Adriamycin, vincristine and vinblastine in multidrug-resistant cells with no effect on drug-sensitive parent P388 cells.

MS-073 (CP-162398) is a P-glycoprotein inhibitor (P-gp). The in vitro resistance to vincristine (VCR) was almost completely reversed in VCR-resistant P388 cells, and the resistance of VCR, adriamycin (ADM), etoposide, and actinomycin D in ADM-resistant hu

Milbemycin A4 oxime, a derivative of milbemycin A4 and a component of milbemycin oxime, exhibits insecticidal and nematocidal activity. At 0.05 mg/kg, it reduces microfilariae of the heartworm D. immitis in naturally infested dogs and inhibits the growth of C. glabrata clinical isolates with MIC80 values of 16 to >32 μg/ml. At 2.5 μg/ml, it blocks fluconazole efflux from C. glabrata clinical isolates (but not from strains lacking CgCDR1 and PDH1 efflux pumps) and reduces MICs of fluconazole and 4-nitroquinoline 1-oxide in wild-type C. glabrata. Furthermore, it enhances adriamycin-induced inhibition of cell growth, increases intracellular accumulation of adriamycin and the P-glycoprotein substrate rhodamine 123 in adriamycin-resistant, but not adriamycin-sensitive, MCF-7 breast cancer cells in a concentration-dependent manner.

FD-211 is a δ lactone originally isolated from M. lutea with anticancer activity.1 It is cytotoxic to adriamycin-susceptible P388, T-24, HeLa, A549, and HL-60 cancer cells (IC50s = 4, 0.5, 1, 1, and 0.2 μg/ml, respectively), as well as adriamycin-resistant HL-60/ADR cells (IC50 = 0.1 μg/ml). FD-211 also inhibits DNA, RNA, and protein synthesis in HeLa cells (IC50 = 1.25 μg/ml for all). |1. Nozawa, O., Okazaki, T., Sakai, N., et al. A novel bioactive δ lactone FD-211. Taxonomy, isolation and characterization. J. Antibiot. (Tokyo) 48(2), 113-118 (1995).

Epifriedelanol (Epifriedelinol) suppresses adriamycin-induced cellular senescence, replicative senescence in human fibroblasts (HDFs) and HUVECs. Because of Epifriedelanol can reduce cellular senescence in human primary cells, it may be used to develop dietary supplements or cosmetics that modulate tissue aging or aging-associated diseases.

Cinobufotalin is a main cardiac toxin in toad, it is a novel anti-HCC agent, it induces growth inhibition and apoptosis in cultured HCC cells through ceramide production. Cinobufotalin is also an effective reversal agent for the multidrug resistance of tu

Topoisomerase I inhibitor 5 is an efficient topoisomerase I inhibitor with an IC50 value, effectively disrupting DNA and inhibiting topoisomerase I activity. It induces apoptosis in MCF-7 cells and arrests the cell cycle at the G1 phase, displaying potency in reversing P-gp-mediated resistance to Adriamycin [1].

Saquayamycin B is a glycoside of aquayamycin that acts on Gram-positive bacteria and inhibits the growth of adriamycin-sensitive and adriamycin-resistant P388 leukemia cells.

1. Schisanhenol (Schizanhenol) can protect against adriamycin induced heart mitochondrial toxicity. 2. Schisanhenol has antioxidative effect on human LDL oxidation, may be through scavenging free radicals. 3. Schisanhenol has anti-apoptosis effect on BACSs, may be related to its inhibition of ROS generation.

Cholesteryl Hemisuccinate Tris Salt is an acidic cholesteryl ester with hepatoprotective and anticancer activity.Cholesteryl hemisuccinate is a membrane stabilizer in dipalmitoylphosphatidylcholine liposomes containing Chaikosaponin-d, which enhances the anticancer efficacy of cisplatin.Cholesteryl hemisuccinate possesses antitumor activity, inhibits tumor Cholesteryl hemisuccinate has antitumor activity, inhibits tumor growth, inhibits the hepatotoxicity of acetaminophen (AAP) and prevents AAP-induced apoptosis of hepatocytes.Cholesteryl hemisuccinate protects rodents against the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform, and galactosamine.